Sign In
Buy CATX
$3.56
-0.0400 (-1.11%)
At Close: Jun 03, 2026
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
02:08pm, Wednesday, 03'rd Jun 2026
Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor called meningioma using its experimental drug [212Pb]VMT-a-NET, broadening a clinical trial that pr
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
10:06am, Wednesday, 03'rd Jun 2026
Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor called meningioma using its experimental drug...
SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical develop
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced t
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
06:30am, Monday, 18'th May 2026
SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical developm
Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
08:00pm, Wednesday, 13'th May 2026
Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
04:07pm, Monday, 11'th May 2026
SEATTLE, May 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical developm
Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field
06:28pm, Monday, 27'th Apr 2026
Perspective Therapeutics (CATX) is advancing radiopharmaceutical therapies, with a pivotal data readouts expected in 2026 in NETs, plus melanoma / solid tumor data. CATX's VMT-α-NET shows promising e
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
06:30am, Friday, 24'th Apr 2026
SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced
SEATTLE, April 20, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced tr
Perspective Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Thursday, 02'nd Apr 2026
SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
04:45pm, Tuesday, 17'th Mar 2026
SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advance
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
04:07pm, Monday, 16'th Mar 2026
SEATTLE, March 16, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical develo
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
11:17am, Tuesday, 17'th Feb 2026
/PRNewswire/ -- Equity-Insider.com News Commentary - More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
07:00am, Tuesday, 17'th Feb 2026
SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatme
